(Q38789875)

English

S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial

scientific article published on 06 April 2017

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

phase III clinical trial

0 references

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

hepatocellular carcinoma

1 reference

based on heuristic

inferred from title

1

object named as

Masatoshi Kudo

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

author name string

Michihisa Moriguchi

2

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Kazushi Numata

3

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Hisashi Hidaka

4

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Hironori Tanaka

5

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Masafumi Ikeda

6

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Seiji Kawazoe

7

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Shinichi Ohkawa

8

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Yozo Sato

9

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Shuichi Kaneko

10

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Junji Furuse

11

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Madoka Takeuchi

12

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Xuemin Fang

13

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Yoshito Date

14

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Masahiro Takeuchi

15

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Takuji Okusaka

16

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

publication date

6 April 2017

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

The lancet. Gastroenterology & hepatology

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

407-417

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930072-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930072-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930072-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930072-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930072-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930072-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930072-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I/II study of the pharmacokinetics, safety and efficacy of S-1 in patients with advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930072-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Pilot study of combination chemotherapy of S-1, a novel oral DPD inhibitor, and interferon-alpha for advanced hepatocellular carcinoma with extrahepatic metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930072-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination therapy with S-1 and pegylated interferon alpha for advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930072-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930072-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A new initiative on precision medicine

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930072-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A predictive enrichment procedure to identify potential responders to a new therapy for randomized, comparative controlled clinical studies

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930072-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930072-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930072-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Detecting an overall survival benefit that is derived from progression-free survival

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930072-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Post-progression survival and progression-free survival in patients with advanced hepatocellular carcinoma treated by sorafenib.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930072-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Report of the 19th follow-up survey of primary liver cancer in Japan

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930072-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Design and endpoints of clinical trials in hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930072-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Multiplication of alpha-fetoprotein and protein induced by vitamin K absence-II is a powerful predictor of prognosis and recurrence in hepatocellular carcinoma patients after a hepatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930072-9

7 January 2021

based on heuristic

inferred from DOI database lookup

GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930072-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930072-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I and pharmacokinetic study of 5-fluorouracil administered by 5-day continuous infusion in patients with hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930072-9

7 January 2021

based on heuristic

inferred from DOI database lookup

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930072-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930072-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930072-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930072-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S2468-1253(17)30072-9

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38789875&oldid=1786896113"